Asterias Biotherapeutics Inc. Series A
AST
AST was delisted on the 7th of March, 2019.
42 hedge funds and large institutions have $4.43M invested in Asterias Biotherapeutics Inc. Series A in 2014 Q4 according to their latest regulatory filings, with 42 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
400% more call options, than puts
Call options by funds: $5K | Put options by funds: $1K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.95M |
| 2 |
First Eagle Investment Management
New York
|
+$595K |
| 3 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
+$232K |
| 4 |
Goldman Sachs
New York
|
+$144K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$113K |
Top Sellers
AST Hedge Fund Activity: Q4 2014 in Review
42 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Series A (AST) for Q4 2014, worth a combined $4.43M.
Buyers outnumbered sellers: 42 funds opened new AST positions and 0 closed out — a net gain of 42 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $3.95M.
- 42 institutional investors held Asterias Biotherapeutics Inc. Series A (AST) as of Q4 2014, up from 0 in Q3 2014.
- Funds reported $4.43M of Asterias Biotherapeutics Inc. Series A stock for Q4 2014.
- 42 funds opened new Asterias Biotherapeutics Inc. Series A positions in Q4 2014 and 0 closed out, a net change of +42 holders.
- The largest Asterias Biotherapeutics Inc. Series A buyer in Q4 2014 was Fidelity Investments, an estimated $3.95M added.
Based on aggregated 13F filings for Q4 2014.